Proventus

Making Life Fairer

 

Help-Line 01233 334 879

 

Working together to make a difference

Disease Modifying Drugs & Therapies

 

 

Find Us Here

You tube
Follow Provpeter on Twitter
You Tube
twitter

If you have experienced any adverse side effects from a medication or therapy - Report it

Teriflunomide                                                                                                                                                                                                                                

Affects the immune system by blocking the action of a specific set of immune cells called T cells, which are thought to be responsible for causing damage to the brain and spinal cord in people with MS. Other immune functions are thought to be left intact, affording people with MS some immune protection against pathogens.

Side effects may occur                                                                                                                                                                                                                 

 

Phase II trial results were published in 2006 involving two different doses of Teriflunomide over 36 weeks in a trial involving 179 people with relapsing remitting MS, 157 people with secondary progressive MS who still experience relapses and 22 who received placebo. MRI brain scans were performed every 6 weeks.
 

Both doses of drug tested in the study were associated with reduced numbers of active MRI lesions.

Fewer people receiving the higher dose of Teriflunomide demonstrated disability increase compared to placebo. No effect on relapse rate was observed.

One phase III study called TEMSO involving 870 people with MS, assessing if teriflunomide is able to reduce the frequency of relapses and the accumulation of disability began in Sept 2004 and was completed in June 07.

The results have not yet been published. ClinicalTrials.gov Identifier NCT00134563

Another world-wide study involving 780 people with multiple sclerosis is attempting to assess if teriflunomide is able to reduce the number of people who go on to develop clinically definite multiple sclerosis after having their first symptoms, compared to placebo.

This began in February 2008. ClinicalTrials.gov Identifier: NCT00622700

Other phase II studies are assessing the effects of teriflunomide in conjunction with beta interferon therapies.

 

Top of Page